Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk ...

Fintel reports that on June 23, 2025, HC Wainwright & Co. initiated coverage of Septerna (NasdaqGM:SEPN) with a Buy ...

Analysts have set 12-month price targets for Septerna, revealing an average target of $20.0, a high estimate of $26.00, and a low estimate of $11.00. Witnessing a positive shift, the current average ...

Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company after a year of decline that ultimately led to the firing of its CEO last ...

Septerna reported a net loss for $(21.5m) in Q1 2025, versus a net loss of $(14.2m) in the prior year period, and reported a cash position of $398m, down from $421m in Q1 2024.

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it trades over a 20% discount.

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 diabetes, obesity and other cardiometabolic diseases. The exclusive global ...

Septerna is also eligible to receive tiered royalties on global net sales of marketed products. Novo Nordisk will cover all R&D expenses for partnered programs under the collaboration. In addition, ...

Detailed price information for Septerna Inc (SEPN-Q) from The Globe and Mail including charting and trades.

--Septerna, Inc., a biotechnology company pioneering a new era of G protein-coupled receptor drug discovery, today highlighted key business updates and upcoming milestones and reported financial ...

Septerna is also eligible to receive tiered royalties on global net sales of marketed products. Novo Nordisk will cover all R&D expenses for partnered programs under the collaboration.

SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today ...